Authors: Alexandre, J Bleuzen, P Bonneterre, J Sutherland, W Misset, JL Guastalla, JP Viens, P Faivre, S Chahine, A Spielman, M Bensmaine, A Marty, M Mahjoubi, M Cvitkovic, E

Citation: J. Alexandre et al., Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients, J CL ONCOL, 18(3), 2000, pp. 562-573

Authors: Bonneterre, J Spielman, M Guastalla, JP Marty, M Viens, P Chollet, P Roche, H Fumoleau, P Mauriac, L Bourgeois, H Namer, M Bergerat, JP Misset, JL Trandafir, L Mahjoubi, M

Citation: J. Bonneterre et al., Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience, EUR J CANC, 35(10), 1999, pp. 1431-1439

Authors: Ducreux, M Ychou, M Seitz, JF Bonnay, M Bexon, A Armand, JP Mahjoubi, M Mery-Mignard, D Rougier, P

Citation: M. Ducreux et al., Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer, J CL ONCOL, 17(9), 1999, pp. 2901-2908

Authors: Wasserman, E Cuvier, C Lokiec, F Goldwasser, F Kalla, S Mery-Mignard, D Ouldkaci, M Besmaine, A Dupont-Andre, G Mahjoubi, M Marty, M Misset, JL Cvitkovic, E

Citation: E. Wasserman et al., Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics, J CL ONCOL, 17(6), 1999, pp. 1751-1759